# A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Clinical trial · Eli Lilly and Company

- Archive id: nct:NCT05803421
- Published: 2023-04-07
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05803421
- Source URL: https://clinicaltrials.gov/study/NCT05803421
- Provenance: clinicaltrials

## Abstract

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: ACHIEVE-4
- status: COMPLETED
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 2749
- sponsor: Eli Lilly and Company
- conditions: Type 2 Diabetes; Obesity; Overweight or Obesity; Overweight; Cardiovascular Diseases; Chronic Kidney Disease
- interventions: DRUG: Orforglipron; DRUG: Insulin Glargine
- start date: 2023-04-03
- start date type: ACTUAL
- primary completion date: 2026-03-16
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

Cited in dossiers:
- [GLP-1 & Incretin Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.